Navigation Links
Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
Date:6/23/2010

Researchers from Mount Sinai School of Medicine have found why patients with a variant form of xeroderma pigmentosum (XPV), an inherited genetic disorder characterized by extreme sensitivity to the sun, are more susceptible to skin cancers than the general population. The data are published in the current issue of the journal Nature. Their finding sets the stage for research into therapies that would help protect people with XPV from developing skin cancers.

The research team determined that, in the general population, DNA polymerase eta, an enzyme able to overcome the barriers created by sun damage and ultraviolet rays and continue replicating DNA strands, is structured differently from any other polymerase. However, in people with XPV, since this enzyme is missing, they are unable to bypass this damage, causing the replication process to stall, resulting in mutations and extremely high susceptibility to skin cancer.

Researchers have never been able to fully determine a structural basis for why the enzyme can get around UV damage. After nearly a decade of research, the Mount Sinai team successfully developed a crystal model, or a three dimensional chemical derivation, of the enzyme. They determined that in the general population, DNA polymerase eta suppresses skin cancer because the active site, where chemical reactions required to replicate DNA take place, can adjust much better to UV damage than any other DNA polymerase.

"We have been unable to study how DNA polymerase eta can replicate through UV damage because we did not have a crystal structure of the enzyme to study," said Aneel K. Aggarwal, Ph.D, Professor, Structural and Chemical Biology, Mount Sinai School of Medicine. "Our team succeeded in developing this structure and determining what makes this enzyme unique."

In conjunction with Drs. Louise and Satya Prakash's group at the University of Texas Medical Branch in Galveston, Texas, Dr. Aggarwal's team generated crystals and analyzed them using X-rays. They determined that the active site of DNA polymerase eta is structured in such a way that it can easily accommodate the UV induced DNA lesions and replicate through them.

"Now that we know the structural basis for the suppression of skin cancers by this enzyme, one question for the future is if there's a way to restore its function in people with XPV and reduce their risk for cancer," said Dr. Aggarwal.

According to the National Center for Biotechnology Information of the National Institutes of Health, xeroderma pigmentosum is an inherited genetic disorder characterized by severe sun sensitivity resulting in blisters and precancerous freckles, benign tumors on the skin and eyes, blurry vision and eye pain from atrophic eye lids, and neurologic symptoms including cognitive decline.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Mount Sinai finds prenatal exposure to certain chemicals affects childhood neurodevelopment
2. Flat Screen TV Stands, TV Mounting Brackets and More: New Site, New Sale, Free Shipping
3. Mountain Home Experiences a Huge Response to Their Ground Breaking Free Lean Six Sigma Certification Offer
4. UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance
5. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
6. Childhood obesity: Its not the amount of TV, its the number of junk food commercials
7. New York and Connecticut Drug Rehab Center Mountainside Weighs In on Latest White House Budget
8. Mountain Home 'Doing the Right Thing Really is the Best Business Approach'
9. Dominos Pizza(R) Raises Record Amount for St. Jude Childrens Research Hospital
10. Excitement Surrounding "Unveil Your Pink" Mounts!
11. Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... been officially recognized for its September 2016 donation of dog beds to the ... received three awards and honors for its contribution from city and state officials. ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... the success of the annual PAINWeek National Conference. On October 7, at the ... an educational and exciting program providing busy clinicians and allied healthcare practitioners with ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), ... magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist ... incorporate magnesium, a critical property for bone health and development. , “We’re excited ...
(Date:9/19/2017)... ... September 19, 2017 , ... Premiere Long Island dental office Gold Coast Smiles ... of the best dentists in America under age 40 by Incisal Edge magazine. ... the magazine features the best 40 dentists under the age of 40 renowned for ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... , the most prestigious ranking of the nation's fastest-growing private companies. The list ... most dynamic segment— its independent small and midsized businesses. Endo-Systems is a leading ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: